At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
ACC-001 +2 morebiological
Likely dose
ACC-001 30 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.
In Brief
A Phase 2 clinical trial evaluating ACC-001 and QS-21 for Alzheimer's Disease. Completed, enrolled 32 participants across 9 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesJapan
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionJan 2013
TodayJul 2026
First PostedAug 14, 2009
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.9 years ago
Interventions
ACC-001biological
IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
QS-21other
IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
QS-21other
IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12